Compare SGML & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGML | CAPR |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2021 | 2011 |
| Metric | SGML | CAPR |
|---|---|---|
| Price | $13.09 | $33.27 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $16.75 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 3.1M | 921.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,270,465.00 |
| Revenue This Year | $31.30 | N/A |
| Revenue Next Year | $136.50 | $17,308.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.25 | $4.30 |
| 52 Week High | $16.88 | $40.37 |
| Indicator | SGML | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 72.07 |
| Support Level | $10.26 | $22.09 |
| Resistance Level | $16.78 | $40.37 |
| Average True Range (ATR) | 1.14 | 1.84 |
| MACD | -0.16 | 0.46 |
| Stochastic Oscillator | 26.08 | 71.58 |
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.